Compare Ambarella Inc (AMBA) vs Smith & Nephew plc (SNN) Price & Performance

Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.

Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.

Smith & Nephew (SNN) trades at $30.70, up 0.99% with a bullish technical signal supported by moving averages. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B (2024-2025) and net income margin expanding to 10.14%. Recent developments include new medical guidance publications and robotics platform advancements, while analyst consensus remains cautious with 68% hold ratings.

SNN presents a mixed outlook with strong profitability metrics and positive cash flow trends offset by recent earnings misses and conservative analyst sentiment. Investment opportunity lies in the company's medical technology innovations and margin expansion, though risks include competitive pressures and execution challenges in meeting growth targets.